 Home > Biochemistry News > Biotechnology News > Gene therapy targeting neurons in the substantia nigra is expected to improve the efficacy of levodopa in the treatment of Parkinson's disease

Gene therapy targeting neurons in the substantia nigra is expected to improve the efficacy of levodopa in the treatment of Parkinson's disease

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

what sativa used

what tramadol treat

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the advanced stages of Parkinson's disease, the drug levodopa becomes less effective in treating symptoms due to the unstoppable loss of dopamine-releasing neurons

The gene therapy restores the ability of neurons in the substantia nigra to convert levodopa to dopamine

In this new study, the authors also explain why dopamine-releasing neurons (that is, dopamine-releasing neurons, also called dopaminergic neurons) are lost in Parkinson's disease

These findings in mice may help identify humans in the early stages of Parkinson's disease and develop therapies to slow the progression of the disease and treat advanced disease

Key new discoveries:

(1) Mitochondria in dopamine-releasing neurons are damaged enough to cause Parkinson's disease

(2) Contrary to the thinking in the past 30 years, the appearance of motor symptoms of Parkinson's disease requires the loss of dopamine release in the substantia nigra of the brain

(3) These authors confirmed that gene therapy targeting the substantia nigra effectively improves the efficacy of levodopa in relieving symptoms

In addition to providing a clear target for remission therapy, this new study also provides a model of Parkinson's disease before clinical symptoms appear

Note: The original text has been deleted

Reference materials:

Patricia González-Rodríguez et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.